In:
mBio, American Society for Microbiology, Vol. 15, No. 5 ( 2024-05-08)
Abstract:
As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19-specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that the administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients.
Type of Medium:
Online Resource
ISSN:
2150-7511
DOI:
10.1128/mbio.00400-24
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
2024
detail.hit.zdb_id:
2557172-2